Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Brambatti, Michela; Darius, Harald; Oldgren, Jonas; Clemens, Andreas; Noack, Herbert; Brueckmann, Martina; Yusuf, Salim; Wallentin, Lars; Ezekowitz, Michael D.; Connolly, Stuart J.; Healey, Jeff S.

doi:10.1016/j.ijcard.2015.05.141

Cited by 79 publications

(80 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with findings from a sub-analysis of the RELY trial in diabetic patients, which showed that diabetic status does not appear to impact the relative safety and efficacy of dabigatran compared to warfarin (8).…”

Section: Accepted Manuscriptsupporting

confidence: 90%

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

Bansilal¹,

Bloomgarden²,

Halperin³

et al. 2015

American Heart Journal

137

107

View full text Add to dashboard Cite

show abstract

Section: Accepted Manuscriptsupporting

confidence: 90%

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

Bansilal¹,

Bloomgarden²,

Halperin³

et al. 2015

American Heart Journal

137

107

View full text Add to dashboard Cite

show abstract

“…In the ROCKET-AF study comparing rivaroxaban and warfarin, there was no significant interaction between diabetes and the risk of hemorrhagic complications [23]. The RE-LY study comparing dabigatran and warfarin showed comparable bleeding rates in patients with diabetes [26]. The analysis showed a significantly reduced rate of intracranial hemorrhage in diabetic patients receiving dabigatran 110 mg BID compared to warfarin, but a non-significant reduction in diabetic patients receiving dabigatran 150 mg BID [26].…”

Section: Diabetic Patientsmentioning

confidence: 99%

“…The RE-LY study comparing dabigatran and warfarin showed comparable bleeding rates in patients with diabetes [26]. The analysis showed a significantly reduced rate of intracranial hemorrhage in diabetic patients receiving dabigatran 110 mg BID compared to warfarin, but a non-significant reduction in diabetic patients receiving dabigatran 150 mg BID [26]. No interaction between diabetic status and the benefits of NOACs was found for the occurrence of ischemic stroke, major bleeding, or intracranial bleeding in the meta-analysis by Patti et al [27].…”

Section: Diabetic Patientsmentioning

confidence: 99%

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

et al. 2017

View full text Add to dashboard Cite

Atrial fibrillation (AF) is associated with an increased risk of ischemic stroke or systemic embolism compared with normal sinus rhythm. These strokes may efficiently be prevented in patients with risk factors using oral anticoagulant therapy, with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) (i.e., direct thrombin inhibitors or direct factor Xa inhibitors). Owing to their specific risk profiles, some AF populations may have increased risks of both thromboembolic and bleeding events. These AF patients may be denied oral anticoagulants, whilst evidence shows that the absolute benefits of oral anticoagulants are greatest in patients at highest risk. NOACs are an alternative to VKAs to prevent stroke in patients with “non-valvular AF”, and NOACs may offer a greater net clinical benefit compared with VKAs, particularly in these high-risk patients. Physicians have to learn how to use these drugs optimally in specific settings. We review concrete clinical scenarios for which practical answers are currently proposed for use of NOACs based on available evidence for patients with kidney disease, elderly patients, women, patients with diabetes, patients with low or high body weight, and those with valve disease.

show abstract

“…However, in nearly 40% of patients with AF, OAC is contraindicated . Moreover, DM patients taking non‐vitamin K oral anticoagulants have a greater absolute thromboembolic risk reduction, but also an increased risk of bleeding . The longer the duration of DM in patients with AF, the greater the risk of thromboembolism …”

Section: Introductionmentioning

confidence: 99%

Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation: Long‐term results

Litwinowicz

Bartuś

Ceranowicz

et al. 2018

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Cited by 79 publications

References 44 publications

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation: Long‐term results

Contact Info

Product

Resources

About